半胱氨酸蛋白酶抑制剂4在胰腺癌临床诊断及预后评估中的价值

doi:10.3969/j.issn.1004-616x.2024.06.007

Abstract

Abstract: OBJECTIVE： To evaluate the value of serum cystatin 4 (CST4) levels in the clinical diagnosis and prognosis evaluation of pancreatic cancer. METHODS： From October 2020 to January 2023，71 newly diagnosed pancreatic cancer patients who were treated in the Fourth Hospital of Hebei Medical University were selected for our study，and their clinical indicators including blood routine，coagulation function，blood biochemistry，and serum tumor markers were collected. Differences in CST4 and other clinical laboratory test results between these patients and patients with benign pancreatic tumors were analyzed. Receiver operating curve (ROC) analysis were performed to evaluate the significance of CST4 in the diagnosis and clinical progression assessment of pancreatic cancer. Kaplan-Meier survival curves were constructed，and multivariate Cox regression analysis was conducted to evaluate the value of CST4 in the clinical prognosis assessment of pancreatic cancer compared with traditional tumor markers：carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA19-9). RESULTS： Compared with the benign tumors group，the proportions and median values of serum CST4，CA19-9，and CEA levels in pancreatic cancer patients were significantly increased (P<0.01). ROC analysis showed that the area under the curve (AUC) of CST4 in the diagnosis of pancreatic cancer was 0.782，and the AUC of CST4 combined with CEA and CA19-9 was significantly higher than that of single detection (AUC=0.930) (P<0.05). CST4 showed higher value in predicting the clinical progression of pancreatic cancer (AUC=0.794)，with a sensitivity of 80.90%，specificity of 70.80%，positive likelihood ratio of 2.77，and an optimal cutoff value of 84.41 U/mL. Prognostic analysis showed that the median survival times of high CST4 group and low CST4 group patients were significantly different at 6.2 months and 25.6 months (P<0.01). Elevated serum CST4 level was identified as an independent risk factor for the prognosis of pancreatic cancer (P<0.05). CONCLUSION： Our data show that serum CST4 level can be used as a clinical auxiliary diagnostic indicator for pancreatic cancer and as an independent risk factor for the prognosis of pancreatic cancer.

Key words: pancreatic cancer, cystatin 4, serum tumor markers, prognosis

CLC Number:

R733.7

GUO Xujuan, JIA Yuming, YAN Xi, ZHAO Hongzheng, GUO Yiyang, ZHANG Jinyan. Clinical value of CST4 in auxiliary diagnosis and prognosis assessment of pancreatic cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 463-469.

References

[1] 徐近. 中国抗癌协会胰腺癌整合诊治指南(精简版)[J]. 中国肿瘤临床, 2023, 50(10): 487-496.
[2] 中华医学会检验分会, 卫生部临床检验中心, 中华检验医学杂志编辑委员会. 肿瘤标志物的临床应用建议[J]. 中华检验医学杂志, 2012, 35(2): 103-116.
[3] 董经茹, 白云鹤, 何京, 等. 基于生物信息学筛选与分析胰腺癌的生物标志物半胱氨酸蛋白酶抑制剂S[J]. 中国免疫学杂志, 2022, 38(24): 3030-3034.
[4] CAI J, CHEN H D, LU M, et al. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis[J]. Cancer Lett, 2021, 520: 1-11.
[5] ZHAO Z Y, LIU W. Pancreatic cancer: a review of risk factors, diagnosis, and treatment[J]. Technol Cancer Res Treat, 2020, 19: 1533033820962117.
[6] ZHANG W, JI L C, WANG X J, et al. Nomogram predicts risk and prognostic factors for bone metastasis of pancreatic cancer: a population-based analysis[J]. Front Endocrinol, 2021, 12: 752176.
[7] GE L, PAN B, SONG F J, et al. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy[J]. BMJ Open, 2017, 7(12): e018175.
[8] FAHRMANN J F, SCHMIDT C M, MAO X Y, et al. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection[J]. Gastroenterology, 2021, 160(4): 1373-1383.e6.
[9] PAVAI S, YAP S F. The clinical significance of elevated levels of serum CA 19-9[J]. Med J Malaysia, 2003, 58(5): 667-672.
[10] PORUK K E, GAY D Z, BROWN K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates[J]. Curr Mol Med, 2013, 13(3): 340-351.
[11] HOGENDORF P, SKULIMOWSKI A, DURCZY-SKI A, et al. A panel of CA19-9, Ca125, and Ca15-3 as the enhanced test for the differential diagnosis of the pancreatic lesion[J]. Dis Markers, 2017, 2017: 8629712.
[12] GU Y L, LAN C, PEI H, et al. Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy[J]. Asian Pac J Cancer Prev, 2015, 16(15): 6569-6573.
[13] ZHANG Y Q, ZHANG J J, SONG H J, et al. Overexpression of CST4 promotes gastric cancer aggressiveness by activating the ELFN2 signaling pathway[J]. Am J Cancer Res, 2017, 7(11): 2290-2304.
[14] SHI D, ZHOU Z, ZHANG S. miRNA-6715-5p inhibits cellular proliferation and invasion in colorectal cancer by directly targeting CST4[J]. J Oncol, 2021, 2021: 7615712.
[15] CHEN Y Y, LI B P, WANG J F, et al. Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer[J]. BMC Cancer, 2023, 23(1): 1122.
[16] HUANG M Y, YANG Z Y, REN J Q, et al. The diagnosis significance of serum cysteine protease inhibitors (CST4) in colorectal cancer[J]. Technol Cancer Res Treat, 2023, 22: 15330338231164232.
[17] 赵安娜, 吴爽, 张海平, 等. CST4在胃癌人群检测中的临床意义[J]. 分子诊断与治疗杂志, 2023, 15(4): 559-563.
[18] SCARÀ S, BOTTONI P, SCATENA R. CA 19-9: biochemical and clinical aspects[J]. Adv Exp Med Biol, 2015, 867: 247-260.
[19] VAN MANEN L, GROEN J V, PUTTER H, et al. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis[J]. Biomarkers, 2020, 25(2): 186-193.
[20] 张定富, 吴秋芳, 戈长征. 肿瘤标记物CA19-9、CA242对胰腺癌转移和预后预测价值的分析[J]. 现代肿瘤医学, 2017, 25(8): 1258-1260.

Clinical value of CST4 in auxiliary diagnosis and prognosis assessment of pancreatic cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	KANG Xiaopei, GUO Zhenjiang, LIU Fangzhen. The expression and prognosis of BAF57 in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 379-383.
[2]	ZHU Wenbiao, YAN Chunmei, QIU Bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression of secreted frizzled-related protein 4 in hepatocellular carcinoma, and relationship with clinicopathological index and prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 288-293,297.
[3]	MA Sheng, WANG Xijun, LIU Zhenrong, WANG Yaru, HU Nan, RONG Weiqi, XIAO Ting. The expression and clinical significance of MFSD2A in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 187-194.
[4]	ZHANG Yi, GAO Han, ZHENG Zhanyue, TAN Qitao, YANG Minli, SUN Yan. Screening of key genes for prognosis of glioma based on public databases [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 195-201.
[5]	SONG Zhenming, YU Yunliang, YANG Jinmei, LIU Kun, GAI Chanchan, MA Chunyu. Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 208-218.
[6]	FU Yongqing, XU Sanhui, ZHAO Yan, WANG Lili. Relationships between SPP1, DEC1, C1QTNF6 and clinicopathologic outcomes of oral squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 107-111,117.
[7]	TONG Jing, WANG Dan. Expression and significance of miR-544a in patients with colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 124-128,137.
[8]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[9]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[10]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[11]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[12]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[13]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[14]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[15]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.